文献速递心力衰竭与心肌病

恩格列净对急性心衰住院患者症状、体力限制和生活质量的影响:EMPULSE试验结果

Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.
PubMed 文献 · Circulation · 2022-04-04

EMPULSE试验将530例急性心衰住院患者随机分配至恩格列净10mg每日一次或安慰剂治疗90天,使用KCCQ评估健康状态。结果显示恩格列净在基线症状严重程度各三分位组均带来临床获益,且早在15天即改善症状、体力限制和生活质量,并持续至90天。

要点

  • 恩格列净改善急性心衰住院患者症状、体力限制和生活质量,15天起效并持续90天。
  • 临床获益在各基线KCCQ-TSS三分位组一致,无异质性。
  • 90天时KCCQ各领域评分较安慰剂显著改善。

核心结论

  • 急性心衰住院患者启动恩格列净治疗可带来临床获益,且不受基线症状严重程度影响。
  • 恩格列净改善症状、体力限制和生活质量,15天即可观察到获益并维持至90天。

研究设计与样本

  • EMPULSE试验为随机对照试验,患者因急性心衰住院,随机分配至恩格列净10mg每日一次或安慰剂治疗90天。
  • 共随机530例患者,每组265例;在随机化时及第15、30、90天使用KCCQ评估健康状态。

主要发现

  • 基线KCCQ-TSS总体较低,均值(标准差)为40.8(24.0)分。
  • 恩格列净在基线KCCQ-TSS各三分位组均带来临床获益,无治疗效应异质性(Win Ratio从最低到最高三分位分别为1.49 [95%CI 1.01-2.20]、1.37 [95%CI 0.94-1.99]、1.48 [95%CI 1.00-2.20],交互作用P=0.94)。
  • 第90天时,恩格列净组KCCQ-TSS、体力限制、生活质量、临床总结和总体总结评分较安慰剂组改善更显著(安慰剂校正平均差异分别为4.45分 [95%CI 0.32-8.59],P=0.03;4.80分 [95%CI 0.00-9.61],P=0.05;4.66分 [95%CI 0.32-9.01],P=0.04;4.85分 [95%CI 0.77-8.92],P=0.02;4.40分 [95%CI 0.33-8.48],P=0.03)。

临床怎么用

  • 对于急性心衰住院患者,可考虑启动恩格列净10mg每日一次以改善症状、体力限制和生活质量。
  • 恩格列净的获益在15天即可显现,并持续至90天,且不受基线症状严重程度影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients hospitalized for acute heart failure experience poor health status, including a high burden of symptoms and physical limitations, and poor quality of life. SGLT2 (sodium-glucose cotransporter 2) inhibitors improve health status in chronic heart failure, but their effect on these outcomes in acute heart failure is not well characterized. We investigated the effects of the SGLT2 inhibitor empagliflozin on symptoms, physical limitations, and quality of life, using the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the EMPULSE trial (Empagliflozin in Patients Hospitalized With Acute Heart Failure Who Have Been Stabilized). METHODS: Patients hospitalized for acute heart failure were randomized to empagliflozin 10 mg daily or placebo for 90 days. The KCCQ was assessed at randomization and 15, 30, and 90 days. The effects of empagliflozin on the primary end point of clinical benefit (hierarchical composite of all-cause death, heart failure events, and a 5-point or greater difference in KCCQ Total Symptom Score [TSS] change from baseline to 90 days) were examined post hoc across the tertiles of baseline KCCQ-TSS. In prespecified analyses, changes (randomization to day 90) in KCCQ domains, including TSS, physical limitations, quality of life, clinical summary, and overall summary scores were evaluated using a repeated measures model. RESULTS: In total, 530 patients were randomized (265 each arm). Baseline KCCQ-TSS was low overall (mean [SD], 40.8 [24.0] points). Empagliflozin-treated patients experienced greater clinical benefit across the range of KCCQ-TSS, with no treatment effect heterogeneity (win ratio [95% CIs] from lowest to highest tertile: 1.49 [1.01-2.20], 1.37 [0.94-1.99], and 1.48 [1.00-2.20], respectively; P for interaction=0.94). Beneficial effects of empagliflozin on health status were observed as early as 15 days and persisted through 90 days, at which point empagliflozin-treated patients experienced a greater improvement in KCCQ TSS, physical limitations, quality of life, clinical summary, and overall summary (placebo-adjusted mean differences [95% CI]: 4.45 [95% CI, 0.32-8.59], P=0.03; 4.80 [95% CI, 0.00-9.61], P=0.05; 4.66 [95% CI, 0.32-9.01], P=0.04; 4.85 [95% CI, 0.77-8.92], P=0.02; and 4.40 points [95% CI, 0.33-8.48], P=0.03, respectively). CONCLUSIONS: Initiation of empagliflozin in patients hospitalized for acute heart failure produced clinical benefit regardless of the degree of symptomatic impairment at baseline, and improved symptoms, physical limitations, and quality of life, with benefits seen as early as 15 days and maintained through 90 days. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT0415775.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kosiborod, Angermann, Collins, et al. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation. 2022. PMID: 35377706. doi:10.1161/CIRCULATIONAHA.122.059725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。